Lexaria Bioscience Corp. filings document a Nevada biotechnology company developing and licensing DehydraTECH, its oral drug delivery platform. Registration statements and periodic disclosure materials describe the company's intellectual property licensing segment, research and development activities, B2B initiatives, common stock, warrants, stock options, and risk factors tied to its technology and commercialization model.
Lexaria's 8-K filings record material financing and capital-structure events, including securities purchase agreements, registered direct offerings, concurrent private placement warrants, and the termination of an at-the-market sales agreement. Other filings cover annual meeting voting results, auditor appointment, Nasdaq listing-compliance notices for common stock, and Form 25 records involving warrant listing and registration status.
Lexaria Bioscience Corp. (LEXX) registers up to 923,827 common shares for resale by selling stockholders, all issuable upon exercise of Series A, Series B and placement-agent warrants. Lexaria receives no proceeds from stockholder resales; cash exercise of the warrants would provide an aggregate $11,760,182. Lexaria intends, if it receives proceeds, to use them for future research and development, working capital and general corporate purposes. The warrants may expire unexercised.
The Series A and Series B warrants each cover 453,969 shares and have a $12.67 exercise price. Both are immediately exercisable; Series A has a five-year term and Series B an 18-month term, each from the Effective Date defined in the Inducement Letters. Placement-agent warrants cover 15,889 shares, are immediately exercisable and have a $16.15 exercise price and a five-year term. Common shares outstanding were 2,106,528 as of October 1, 2026. The prospectus notes that the auditor’s report on the incorporated 2025 financial statements contains an explanatory paragraph regarding Lexaria’s ability to continue as a going concern.
Lexaria Bioscience Corp. is registering up to 923,827 common shares for resale by selling stockholders; all are issuable upon warrant exercise. The stockholders may not sell before the registration statement is effective. Lexaria receives no proceeds from resales; cash exercises of the warrants could provide an aggregate $11,760,182, although the warrants may expire unexercised. Any exercise proceeds are intended for future research and development, working capital and other general corporate purposes.
The shares comprise 453,969 Series A and 453,969 Series B warrant shares, each immediately exercisable at $12.67 per share, plus 15,889 placement-agent warrant shares exercisable at $16.15. The Series A and Series B warrants have five-year and 18-month terms, respectively, from the Effective Date. Lexaria had 2,106,528 common shares outstanding as of October 1, 2026. The auditor’s report on the financial statements for the year ended August 31, 2025 includes an explanatory paragraph about the company’s ability to continue as a going concern.
Lexaria Bioscience Corp. (LEXX) filed a Form D for an exempt offering of warrants under Rule 506(b) of Regulation D. The company reports a total amount sold of $113,492, with no remaining amount to be sold, from warrants issued in a warrant inducement agreement where holders agreed to exercise their warrants at market price in exchange for 2x replenishment warrants. H.C. Wainwright & Co. acted as placement agent and received compensation equal to 7% of monies received for the warrants, plus an additional $402,625.10 representing 7% of proceeds from the exercise of warrants under the inducement agreement. The issuer indicates annual revenue in the $5,000,001 to $25,000,000 range.
Lexaria Bioscience Corp. (LEXX) entered into definitive agreements for the immediate exercise of outstanding warrants to purchase 453,969 shares of common stock at a reduced exercise price of $12.92 per share, with closing expected on or about September 9, 2026, subject to customary conditions.
In return for cash exercise of these registered warrants, Lexaria will issue in a private placement new unregistered Series A and Series B warrants for up to 453,969 shares each, both exercisable immediately at $12.67 per share. Series A warrants will expire five years after the effective date of a resale registration statement, while Series B warrants will expire eighteen months after that date.
The transaction is expected to generate approximately $5.9 million in gross proceeds before fees, which, together with a recently received $2.6 million tax rebate from the Australian Tax Office, is expected to be used for working capital and to support operations and research and development programs in 2027. Lexaria highlights its DehydraTECH drug delivery platform and a portfolio of 66 granted patents worldwide.
Lexaria Bioscience Corp. (LEXX) disclosed that its wholly owned Australian subsidiary, Lexaria (AU) Pty Ltd, received an Australian R & D Tax Incentive Credit of AUD$3,666,611.98 on August 28, 2026. The credit relates to research and development costs for its Australian clinical study GLP-1-H24-4.
The funds have been deposited into the subsidiary’s Australian bank account and are intended to be used to pursue additional research and development opportunities in Australia. Lexaria (AU) holds the exclusive rights to use DehydraTECH technology with pharmaceutical GLP-1/GIP and CBD drug products in Australia.
Lexaria Bioscience Corp. reported that on August 17, 2026 it received notice from Nasdaq that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As a result, the previously requested Nasdaq hearing has been cancelled, and the company’s common stock will continue to be listed and trade on The Nasdaq Capital Market. This removes an overhang related to potential delisting and clarifies that the company currently meets Nasdaq’s bid price standards.
Lexaria Bioscience Corp. reported receiving a Nasdaq Capital Market notification on August 4, 2026 that its common stock is subject to delisting for failing to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 bid price within a 180-day compliance period. The company had already completed a reverse stock split on August 3, 2026, after which its shares have been trading on Nasdaq under CUSIP 52886N604 with a bid price currently above the $1.00 requirement. Lexaria has requested a hearing and paid the related fee, which stays any suspension or delisting while it seeks to demonstrate renewed compliance, and it states that it expects to regain full compliance and maintain continuous Nasdaq trading.
Lexaria Bioscience Corp. will implement a 1-for-15 reverse stock split of its common stock effective at 12:01 am EST on August 3, 2026, aiming to increase its share price and regain compliance with Nasdaq’s $1.00 minimum bid price requirement under the Minimum Price Rule.
The split will reduce issued shares from 24,787,446 to approximately 1,652,518 shares, with fractional shares rounded up, and will proportionally adjust all authorized shares, options, and warrants, including their exercise prices. Authorized shares will decrease from 220,000,000 to 14,666,667, while each shareholder’s percentage ownership remains unchanged.
Lexaria plans to request a Nasdaq hearing in connection with its 180-day compliance period and expects to meet the Minimum Price Rule in mid-August. Post-split, the stock will continue trading on Nasdaq under the symbol LEXX with a new CUSIP number 52886N604. The company also highlights its DehydraTECH drug delivery platform and a portfolio of 66 granted patents.
Lexaria Bioscience Corp. reported a net loss attributable to shareholders of $5.0 million for the nine months ended May 31, 2026, improved from $9.2 million a year earlier, driven mainly by lower research and development spending after completion of a prior Phase 1b trial. Revenue fell sharply to $20,000 from $531,923, reflecting expiry of a key licensing contract and reduced B2B activity as the company pivots toward pharmaceuticals.
Cash was $3.5 million with current liabilities of $0.4 million, yielding working capital of $3.7 million, supported by $6.5 million in net equity proceeds from two registered direct offerings. Management nonetheless states there is substantial doubt about the ability to continue as a going concern beyond the first quarter of fiscal 2027 without additional financing or partnerships.
The company continues to develop its DehydraTECH drug delivery platform, focusing on GLP‑1, GIP and glucagon drugs for diabetes and weight loss, and CBD for hypertension under an active FDA IND. It is running new human and animal GLP‑1 studies and exploring strategic options under an extended material transfer agreement with a pharmaceutical counterparty. Lexaria also discloses it received a Nasdaq notice for failing the $1.00 minimum bid price requirement and may need corporate actions, such as a reverse split, to maintain its listing.